Blue Jet Healthcare Ltd
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]
- Market Cap ₹ 9,140 Cr.
- Current Price ₹ 527
- High / Low ₹ 579 / 319
- Stock P/E 52.3
- Book Value ₹ 53.3
- Dividend Yield 0.18 %
- ROCE 30.0 %
- ROE 22.4 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 28.4%
Cons
- Stock is trading at 10.2 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Healthcare BSE Allcap BSE SmallCap Nifty Total Market Nifty Microcap 250
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|
538 | 499 | 683 | 721 | 712 | 722 | |
325 | 292 | 434 | 502 | 482 | 500 | |
Operating Profit | 214 | 207 | 249 | 219 | 229 | 221 |
OPM % | 40% | 41% | 36% | 30% | 32% | 31% |
6 | 9 | 19 | 24 | 19 | 27 | |
Interest | 7 | 5 | 3 | 1 | 0 | 0 |
Depreciation | 18 | 20 | 22 | 25 | 28 | 24 |
Profit before tax | 194 | 190 | 243 | 217 | 220 | 224 |
Tax % | 25% | 26% | 25% | 26% | 26% | |
145 | 142 | 182 | 160 | 164 | 168 | |
EPS in Rs | 24,118.33 | 1,428.57 | 10.47 | 9.23 | 9.44 | 9.68 |
Dividend Payout % | 0% | 0% | 0% | 0% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 13% |
TTM: | -3% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 7% |
TTM: | -3% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 43% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 28% |
Last Year: | 22% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|
Equity Capital | 0.60 | 10 | 35 | 35 | 35 | 35 |
Reserves | 198 | 330 | 487 | 647 | 811 | 889 |
74 | 53 | 19 | 5 | 3 | 1 | |
92 | 143 | 173 | 176 | 211 | 256 | |
Total Liabilities | 364 | 536 | 713 | 862 | 1,059 | 1,181 |
107 | 0 | 156 | 151 | 172 | 268 | |
CWIP | 2 | 3 | 3 | 30 | 147 | 85 |
Investments | 26 | 37 | 94 | 189 | 250 | 293 |
229 | 497 | 460 | 491 | 489 | 535 | |
Total Assets | 364 | 536 | 713 | 862 | 1,059 | 1,181 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
122 | 137 | 146 | 142 | 241 | |
-45 | -61 | -76 | -147 | -264 | |
-72 | -21 | -56 | -4 | -2 | |
Net Cash Flow | 5 | 55 | 14 | -10 | -24 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 80 | 105 | 121 | 121 | 91 |
Inventory Days | 120 | 201 | 133 | 137 | 151 |
Days Payable | 90 | 101 | 72 | 58 | 35 |
Cash Conversion Cycle | 110 | 204 | 183 | 199 | 206 |
Working Capital Days | 64 | 105 | 105 | 121 | 93 |
ROCE % | 58% | 52% | 35% | 30% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Directorate
1d - Re-appointments and appointments of directors at Blue Jet Healthcare.
-
Regulation 30 Of SEBI (LODR), 2015 Intimation Of Consent To Operate At Company''s Mahad Unit, Maharashtra From Maharashtra Pollution Control Board
15 Nov - Consent to operate granted for Mahad unit.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
15 Nov - Intimation of Analyst and Investor meet on November 22, 2024.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
8 Nov - Transcript of the Earnings call with the Analysts / Investors on the Financial Results for the Quarter/Half year ended September 30th, 2024 held on November …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
4 Nov - Submission of audio recording of earnings conference call.
Concalls
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
Product Portfolio
A) Contrast Media Intermediates (67.7% of FY24 revenue)[1]
Contrast media are chemical agents that enhance imaging clarity for diagnostic purposes, making tissues more visible under X-rays, CT scans, MRIs, and ultrasounds. The company supplies critical starting and advanced intermediates to the world's top contrast media manufacturers.